Interferon beta-1a (Interferonum beta-1a)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Interferons

Included in the formulation
  • Avonex®
    lyophilizate w / m 
    Biogen Aidek BV     Netherlands
  • Avonex®
    solution w / m 
    Biogen Aidek BV     Netherlands
  • Genfaxon®
    solution PC 
    Laboratory Tutor SAASIFAA     Argentina
  • Rebif®
    solution PC 
    Merck Serono S.A.     Switzerland
  • SynnoWex
    lyophilizatesolution w / m 
    Sia AFS, LLC     Russia
  • Theberifer®
    solution PC 
    BIOCAD, CJSC     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    7 nosologies

    АТХ:

    L.03.A.B.07   Interferon beta-1a

    Pharmacodynamics:

    The preparation is a recombinant human interferon obtained in the culture of Chinese hamster ovary cells. It binds to specific receptors on the cell membrane, triggers a cascade of intercellular interactions leading to the expression of numerous gene products and markers: protein Mx, 2 ', 5'-oligoadenylate synthetase, β-2-microglobulin and neopterin. The drug has an immunomodulatory, antiproliferative and antiviral effect. This interferon helps reduce the damage to the nervous system that occurs with multiple sclerosis.

    Pharmacokinetics:

    Bioavailability with intramuscular injection - 40%, with subcutaneous - 3 times lower (subcutaneous injection can not replace intramuscular injection).With intramuscular injection, the time to reach the maximum concentration (coincides with the peak of antiviral activity) is 9.8 hours (3-15 hours), with subcutaneous injection - 7.8 hours (3-18 hours). Half-life - 10 hours for intramuscular injection, 8.6 hours for subcutaneous injection. The biological response occurs when administered at a dose of 15-75 μg. Pharmacokinetics in patients with multiple sclerosis has not been studied.

    Indications:

    Recurrent multiple sclerosis (with at least 2 relapses of neurological dysfunction within 3 years and no signs of continuous progression of the disease between relapses).

    ICD-10

    VI.G35-G37.G35   Multiple sclerosis

    Contraindications:

    - severe depression and / or suicidal ideation;

    - bVariability and breastfeeding;

    - ghypersensitivity;

    - epilepsy in the absence of effect from the application of appropriate therapy;

    - atozrast up to 12 years.

    Carefully:

    - depression;

    - convulsions in the anamnesis;

    - kidney failure;

    - liver failure;

    - oppression of bone marrow hematopoiesis;

    - angina pectoris;

    - severe heart failure;

    - arrhythmias.

    Pregnancy and lactation:

    Category FDA - C. The drug is contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Subcutaneously at 22-44 μg 3 times a day at the same time, the interval between administrations is not less than 48 hours. For the first two weeks, the recommended dose is 8.8 μg, 3-4 weeks - 22 μg, starting from the fifth week - 44 μg.

    Intramuscularly 30 mcg once a day.

    The duration of the course of treatment is determined by the doctor.

    Side effects:

    From the gastrointestinal tract: diarrhea, vomiting, loss of appetite, liver damage, abdominal pain

    From the nervous system: dizziness, depression, depersonalization, sleep disturbance, nervousness, suicidal ideation, convulsive seizures.

    From the cardiovascular system: palpitations, peripheral vasodilation, cardiac arrhythmias, chest pain

    Other: redness, pallor of the skin, necrosis in the area of ​​administration, ecchymosis, arthralgia, urticaria, leukopenia, thrombocytopenia, swelling and tenderness at the site of injection, skin rash, influenza-like symptoms, lymphocytopenia, elevation of the level of hepatic transaminases, gamma-glutamyl transferase and alkaline phosphatase, development of infections, including Herpes zoster, Herpes simplex, muscle spasm, alopecia, vaginitis, ovarian cyst, nevus.

    Overdose:

    Not described.

    Treatment is symptomatic.

    Interaction:

    The drugs that suppress the function of the bone marrow are the enhancement of the myelosuppressive effect.

    Compatible with glucocorticoids, adrenocorticotropic hormone. Interferons reduce the activity of enzymes associated with cytochrome P450.

    Caution should be exercised when prescribing with medicines, the clearance of which is largely dependent on the cytochrome P450 system (antiepileptic drugs, antidepressants), sincethe drug reduces the activity of cytochrome system isoenzymes P450.

    Special instructions:

    At the beginning of treatment, additional monitoring of patients with heart diseases is necessary, during treatment it is necessary to control the content of leukocytes and platelets, and also to monitor the functional state of the liver.

    Impact on the ability to manage motor transport and other technical devices

    Adverse reactions from the central nervous system to interferon therapy may influence the ability to drive vehicles and machinery. Be careful.

    Instructions
    Up